Growth Metrics

West Pharmaceutical Services (WST) Net Cash Flow (2016 - 2026)

West Pharmaceutical Services has reported Net Cash Flow over the past 18 years, most recently at -$261.5 million for Q1 2026.

  • Quarterly Net Cash Flow fell 194.15% to -$261.5 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $111.2 million through Mar 2026, up 157.5% year-over-year, with the annual reading at $283.8 million for FY2025, 181.58% up from the prior year.
  • Net Cash Flow was -$261.5 million for Q1 2026 at West Pharmaceutical Services, down from $163.3 million in the prior quarter.
  • Over five years, Net Cash Flow peaked at $163.3 million in Q4 2025 and troughed at -$261.5 million in Q1 2026.
  • The 5-year median for Net Cash Flow is $16.4 million (2024), against an average of -$13.8 million.
  • Biggest five-year swings in Net Cash Flow: tumbled 1522.67% in 2024 and later skyrocketed 895.73% in 2025.
  • Tracing WST's Net Cash Flow over 5 years: stood at $126.5 million in 2022, then tumbled by 146.8% to -$59.2 million in 2023, then soared by 127.7% to $16.4 million in 2024, then skyrocketed by 895.73% to $163.3 million in 2025, then plummeted by 260.13% to -$261.5 million in 2026.
  • According to Business Quant data, Net Cash Flow over the past three periods came in at -$261.5 million, $163.3 million, and $122.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.